| Name | Title | Contact Details |
|---|
Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.
Cannalysis was founded in 2015, in Costa Mesa CA. Initially, Cannalysis exclusively served Southern California with a limited amount of analyses available. As the operational and testing requirements expanded, Cannalysis moved its headquarters to a 12,000 sqft state-of-the-art facility in Santa Ana, CA.
Curve Biosciences (“Curve”), a company bringing precision to chronic disease care, creates products targeting biological changes in tissues that result in the development and progression of chronic diseases. Curve`s Chronic Disease Tissue Atlas (CDTA) uniquely allows the company to discover these precise changes with data from over 250,000 tissues across more than 1,000 clinical studies. Curve is focused on first commercializing its best-in-class blood tests for the $30 billion market of chronic liver diseases while using CDTA to find biomarkers and targets for other conditions.
MBio Diagnostics is now LightDeck Diagnostics! LightDeck Diagnostics believes in a new approach to healthcare, where fast, accurate, simple, low-cost diagnostic tests will be run wherever and whenever they are needed, without compromise. The company`s proprietary LightDeck® platform combines an advanced laser waveguide with novel materials and patented manufacturing techniques to deliver lab-quality results anywhere, in minutes. LightDeck is introducing a portfolio of in vitro diagnostic panels, the first is an on-the-spot test for COVID-19. The LightDeck platform is currently commercialized in veterinary diagnostics and for environmental testing. Learn more at www.LightDeckDx.com Platform Technology The LightDeck platform consists of a robust, portable fluorescence analyzer and disposable, multiplex test cartridges. The LightDeck® platform was designed to meet customer requirements: • Quality: Highly sensitive tests that deliver lab-quality results • Quick: Actionable data in as little as 5 minutes with a simple procedure • Quantitative: More data to inform treatment decisions • Multiplex: Multiple related tests for better precision plus internal quality control to maximize safety The test procedure is simple enough that an untrained user can perform testing almost anywhere. Panels can be configured to run multiple related tests simultaneously to help diagnosis or rule-out a specific condition. Internal quality control runs with every test to ensure quality and not report questionable results.
Ziemer USA INC is a Wood River, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.